RNS Number : 9686U
ValiRx PLC
03 July 2024

3 July 2024

ValiRx PLC

("ValiRx" or the "Company")

Proposed Director Appointment

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces the proposed appointment of Cathy Tralau-Stewart as an Executive Director of the Company, subject to standard regulatory due diligence. Cathy is currently the Chief Scientific Officer of the Company.

Cathy is a highly experienced drug discovery pharmacologist who has led many successful projects which have resulted in a number of marketed products and many other clinical candidate molecules. She has led discovery projects, and due diligence on over 500 early drug discovery projects in a wide range of therapeutic areas.

Following her PhD in Clinical Sciences (Cancer therapeutics) at University College London, Cathy worked in pre-clinical & early clinical drug discovery at GSK. In 2007 she founded the Imperial College London Drug Discovery Centre. In 2013 Cathy moved to the West Coast USA where she led The UCSF catalyst translational program and was an Associate Professor of Bioengineering & Therapeutic Sciences. Subsequently she joined Takeda Pharmaceuticals in External Innovation (2018-2021), leading an extensive network of academic alliances along the West Coast (UC San Diego, Stanford University, The University of Washington & The Fred Hutch Cancer Centre, Seattle). In 2021, Cathy returned to the UK and held Chief Scientific Officer positions at C4X Discovery. Cathy is also Executive Director of The Milner Therapeutics Institute, University of Cambridge.

A further announcement will be made in due course.

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO	**Tel: +44 (0) 2476 796496** **www.valirx.com** Suzanne.Dilly@valirx.com
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** **www.vformation.biz** lucy@vformation.biz sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/ Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**
Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAEAXXDELNLEEA